One of the UK’s major medical cannabis providers, Sapphire Clinics, is to rebrand as Curaleaf Clinic in the new year.
Sapphire was the first medical cannabis clinic to open in the UK in July 2019, and later joined the Curaleaf family in January 2022 as a subsidiary of Curaleaf International.
Effective as of 8 January, 2024, the rebrand will primarily impact non-clinical operations, including the website and external communications with the aim of presenting a ‘more unified’ front to patients and healthcare professionals.
The clinic will continue to be regulated by the Care Quality Commission and all aspects of operations, services, and leadership will remain unchanged.
Mikael Sodergren, co-founder of Sapphire Clinics and chief medical officer at Curaleaf International, commented: “We first joined the Curaleaf family almost two years ago and are proud of what we’ve achieved together. Rebranding Sapphire Clinics as Curaleaf is the logical next step and allows us to convey our story more effectively and transparently to our patients.
“The future of medical cannabis in the UK is extremely promising. While marking a new chapter for us, our dedication to exceptional medical care remains unchanged. The Clinic deeply appreciates the continued trust and support of its staff, patients, and the wider medical community.”
Here’s what you need to know:
In an announcement, the company has reassured stakeholders that its dedication to providing a high-standard of service remains ‘steadfast’ and will ensure a ‘seamless transition’ for both staff and patients throughout the process
- Clinicians will continue to prescribe to eligible patients any product that meets UK quality standards and that is appropriate based on clinical need
- The UK Medical Cannabis Registry will continue to be central to Curaleaf Clinic, collecting outcomes on medical cannabis prescribing to expand awareness and understanding, providing vital evidence for future NHS funding decisions
- The Sapphire Access Scheme will rebrand to the Curaleaf Access Scheme which provides discounted appointments for those who wish to contribute their data to the UK Medical Cannabis Registry. Patients already enrolled in the Sapphire Access Scheme will notice no change to the cost of their consultations.
- Curaleaf will continue to provide online education for healthcare professionals and patients, as The Sapphire Institute becomes Curaleaf Education.
- The role of the endocannabinoid system in dermatological diseases
- Cannabis may help reduce reliance on other stimulants, finds study
- Greece welcomes ‘new era’ of medical cannabis after seven-year wait
- Spain publishes draft medical cannabis framework, but omits flower
- Broughton: How to design a robust CBD testing strategy
- Medical Cannabis Division of Rokshaw Ltd Rebranding to Curaleaf Laboratories
News5 months ago
FSA drops recommended daily dose of CBD to 10mg – everything you need to know
Pain6 months ago
Medical cannabis ‘effective’ and ‘fast-acting’ for neuropathic pain – study
News4 months ago
UK government accepts ACMD recommendations for CBD products
Industry4 months ago
First UK-grown cannabis medicine expected by end of 2023
News5 months ago
The Netherlands to launch cannabis legalisation pilot December 2023
News6 months ago
BBC documentary highlights ‘pot luck’ of access to cannabis on NHS
Science5 months ago
New cannabis research: cancer, Type 2 diabetes, autism, fibromyalgia and skin disorders
News4 months ago
Europe’s first legal cannabis dispensaries to open under sixth Swiss pilot